3 most recent filings and news items mentioning OTLK. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/OTLK/news?limit=20"
Pull OTLK filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayOutlook Therapeutics announced FDA acceptance of its resubmitted Biologics License Application for ONS-5010/LYTENAVA (bevacizumab-vikg) as a treatment for wet AMD, with a PDUFA target action date of July 29, 2026. If approved, LYTENAVA would be the first FDA-approved ophthalmic f
View filing at SEC.gov →Outlook Therapeutics resubmitted its Biologics License Application for ONS-5010/LYTENAVA to the FDA after successfully appealing a Complete Response Letter, with a Class 1 review designation and expected decision within 60 days. If approved, the product would be the first FDA-app
View filing at SEC.gov →The FDA's Office of New Drugs determined that substantial evidence supports the effectiveness of ONS-5010/LYTENAVA for neovascular age-related macular degeneration following the formal dispute resolution process. Outlook plans to resubmit the biologics license application in June
View filing at SEC.gov →